Rekvina Laboratories Claims Exemption from Annual Secretarial Compliance Report for FY26

1 min read     Updated on 07 Apr 2026, 02:06 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Rekvina Laboratories Limited has claimed exemption from the Annual Secretarial Compliance Report for FY26 under SEBI Regulation 15(2), which applies to listed entities with paid-up equity capital not exceeding Rs 10 crores and net worth not exceeding Rs 25 crores. The exemption covers multiple corporate governance provisions including regulations 17-27 and specific clauses under regulation 46 and Schedule V. The company has formally notified BSE of this exemption status through an official communication dated 06.04.2026.

powered bylight_fuzz_icon
37053399

*this image is generated using AI for illustrative purposes only.

Rekvina Laboratories Limited has officially notified BSE Limited that it is claiming exemption from submitting the Annual Secretarial Compliance Report for the financial year ended 31st March, 2026. The communication, dated 06.04.2026, was addressed to the Department of Corporate Services at BSE.

Regulatory Exemption Details

The company has invoked Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which provides specific exemptions for smaller listed entities. Under this regulation, companies meeting certain financial criteria are exempt from various corporate governance provisions.

Exemption Parameter: Threshold Limit
Paid-up Equity Share Capital: Not exceeding Rs 10 crores
Net Worth: Not exceeding Rs 25 crores
Assessment Period: Last day of previous financial year

Scope of Exemptions

The exemption covers extensive corporate governance provisions under SEBI regulations. The company is relieved from compliance with multiple regulations and specific clauses that typically apply to larger listed entities.

Exempt Regulations:

  • Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 26A, 27
  • Clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46
  • Para C, D and E of Schedule V

Company Information

Rekvina Laboratories Limited operates under CIN L24231GJ1988PLC01145 with its registered office located at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda. The notification was signed by Director Surbhit Mukesh Shah (DIN: 01993300), confirming the company's position regarding the non-applicability of the Annual Secretarial Compliance Report requirement.

The company has requested BSE to acknowledge this exemption claim and take note of its regulatory status for the financial year 2026.

Will Rekvina Laboratories' exemption status impact investor confidence or limit access to institutional funding in the coming quarters?

How might the company's growth trajectory be affected by operating under the smaller entity exemptions rather than full corporate governance compliance?

Could Rekvina Laboratories face challenges if it exceeds the Rs 10 crore paid-up capital or Rs 25 crore net worth thresholds in future financial years?

like20
dislike

Rekvina Laboratories Submits Q4FY26 Dematerialisation Compliance Certificate to BSE

1 min read     Updated on 06 Apr 2026, 10:57 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Rekvina Laboratories Limited filed its Q4FY26 dematerialisation compliance certificate with BSE on 06.04.2026, covering the period from 1st January, 2026 to 31st March, 2026. The certificate, prepared by registrar M/s. Purva Sharegistry India Pvt. Ltd, shows no dematerialisation activity during the quarter, with 'NIL' entries across all parameters including folio numbers, shareholder names, and certificate numbers. This regulatory filing under SEBI (Depositories and Participants) Regulations, 2018 ensures compliance with quarterly reporting requirements for listed companies.

powered bylight_fuzz_icon
37042056

*this image is generated using AI for illustrative purposes only.

Rekvina Laboratories Limited has submitted its quarterly compliance certificate to BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the fourth quarter of fiscal year 2026. The certificate, dated 06.04.2026, covers the period from 1st January, 2026 to 31st March, 2026.

Regulatory Compliance Filing

The compliance certificate was signed by Shah Surbhit Mukeshbhai, Director of Rekvina Laboratories Limited (DIN: 01993300), and submitted to the Department of Corporate Services at BSE Limited. The company trades under scrip code 526075 on the exchange.

Filing Details: Information
Period Covered: 1st January, 2026 to 31st March, 2026
Submission Date: 06.04.2026
Scrip Code: 526075
Director: Shah Surbhit Mukeshbhai
DIN: 01993300

Registrar and Transfer Agent Confirmation

M/s. Purva Sharegistry India Pvt. Ltd, serving as the company's Registrar and Share Transfer Agent, provided the compliance certificate. The agency, registered with SEBI under registration number INR000001112 as Category 1 Registrars to IPO & Share Transfer Agents, confirmed adherence to regulatory requirements for dematerialisation processes.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, certified that all securities received from depository participants during the quarter were properly processed and confirmed to depositories within prescribed timelines. The certificate also confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification.

Dematerialisation Activity Summary

The quarterly report reveals no dematerialisation activity during the Q4FY26 period. The detailed breakdown shows:

Activity Parameter: Status
Folio Numbers: NIL
Shareholder Names: NIL
Certificate Numbers: NIL
Share Quantities: NIL
Dematerialisation Dates: NIL

This indicates that no shareholders opted to convert their physical share certificates to electronic form during the January-March 2026 quarter. The 'NIL' entries across all categories in the dematerialisation details table confirm zero activity in this regard.

Regulatory Framework

The filing ensures compliance with SEBI's quarterly reporting requirements under the Depositories and Participants Regulations, 2018. These regulations mandate that companies submit confirmation certificates regarding their dematerialisation activities, ensuring transparency in the conversion process from physical to electronic securities. The timely submission demonstrates Rekvina Laboratories' commitment to regulatory compliance and corporate governance standards.

What factors might be contributing to zero dematerialisation activity at Rekvina Laboratories, and could this indicate investor sentiment or liquidity concerns?

How might the lack of dematerialisation activity impact Rekvina Laboratories' trading volumes and market accessibility in upcoming quarters?

Will Rekvina Laboratories implement any initiatives to encourage shareholders to convert physical certificates to electronic form for better market participation?

like15
dislike

More News on Rekvina Laboratories